Elfarargy, O., Hassan, M., Bakry, A., Taha, H. (2023). Study of Outcome of Early Breast Cancer Patients Treated with Different Chemotherapy Protocols. The Egyptian Journal of Hospital Medicine, 91(1), 4793-4801. doi: 10.21608/ejhm.2023.300786
Ola M. Elfarargy; Mahmoud Ahmed Mohammed Hassan; Adel Bakry; Heba F. Taha. "Study of Outcome of Early Breast Cancer Patients Treated with Different Chemotherapy Protocols". The Egyptian Journal of Hospital Medicine, 91, 1, 2023, 4793-4801. doi: 10.21608/ejhm.2023.300786
Elfarargy, O., Hassan, M., Bakry, A., Taha, H. (2023). 'Study of Outcome of Early Breast Cancer Patients Treated with Different Chemotherapy Protocols', The Egyptian Journal of Hospital Medicine, 91(1), pp. 4793-4801. doi: 10.21608/ejhm.2023.300786
Elfarargy, O., Hassan, M., Bakry, A., Taha, H. Study of Outcome of Early Breast Cancer Patients Treated with Different Chemotherapy Protocols. The Egyptian Journal of Hospital Medicine, 2023; 91(1): 4793-4801. doi: 10.21608/ejhm.2023.300786
Study of Outcome of Early Breast Cancer Patients Treated with Different Chemotherapy Protocols
Background: If detected and treated early, breast cancer has a chance of being cured. Therapy has progressed utilizing multiple chemotherapeutic regimens with great efficacy and minimal toxicity. Objective: To improve the outcome of patients with early breast cancer by clarifying the most effective adjuvant therapy regimen. Subjects and methods: In a clinicopathological retrospective study, we included 854 patients with non-metastatic breast cancer patients treated at Medical Oncology Department, Maadi Armed Forces Medical Complex and Medical Oncology Department, Zagazig University; from January 2015 to December 2018. Results: Most of our study population 505 patients (59.1%) received adjuvant chemotherapy protocol of (4 AC (Adriamycin and Cytoxan) + 4 taxanes), while the 2nd most common used protocol was 6FAC (Fluorouracil, Adriamycin, and Cytoxan), which was received by 17.7% of patients, on the other hand some patients received 4AC, 3AC+3 taxanes and 4TC protocols. Percentage of our patients who were still alive after 4 years of diagnosis were 86.5% (739 patients). Disease recurrence or metastasis occurred in 317 patients (37.1%) during follow up period ranged from 13-84 months, while 537 patients (62.9%) didn’t experience either recurrence or metastasis to time of study. Conclusion: Early breast cancer is considered potentially curable disease. Disease recurrence or metastasis occurred in 37.1% of our patients. Survival rate after 4 years of diagnosis was 86.5%. The FAC protocol has been used in just 17.7% of our patients, but DFS rate of those patients who received FAC was the highest (73.5%), even superior to AC+Taxanes.